Acute interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer after crizotinib therapy

Oxford Medical Case Reports

Volumn 2014, Issue 1, 2014, Pages 11-12

  Maka, Vinayak V ^a   Krishnaswamy, Uma Maheshwari ^a   Kumar, N Anil ^a   Chitrapur, Rohith ^a   Kilara, Nalini ^a  

^a M S RAMAIAH MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; PREDNISOLONE;

ADULT; ARTICLE; BRONCHOSCOPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRACKLE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PALLIATIVE THERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 85007519064     PISSN: None     EISSN: 20538855     Source Type: Journal    
DOI: 10.1093/omcr/omu004     Document Type: Article

References (10)

1. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-66.
2. Ou S-HI, Jänne PA, Bartlett CH, Tang Y, Kim D-W, Otterson GA, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-22.
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
4. Kim DW, Ahn MJ, Shi Y, De Pas T, Yang PC, Riely GJ, et al. Results of a global phase II study with crizotinib inALK-positive non-small cell lung cancer NSCLC. J Clin Oncol 2012;30:15 (suppl; abstr 7533).
5. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-556.
6. U.S. Food and Drug Administration. [FDA homepage] Label approved on 11/20/2013 (PDF) for XALKORI, NDA no. 202570. Reference ID: 3410361, para 5.2, p. 4. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202570s006lbl.pdf
7. Tamiya A, Okamoto I, Miyazaki M, Shimizu S, Kitaichi M, Nakagawa K, et al. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:e15-7.
8. Ono A, Takahashi T, Oishi T, Sugino T, Akamatsu H, Shukuya T, et al. Acute lung injury with alveolar hemorrhage as adverse drug reaction related to crizotinib. J Clin Oncol 2013;31:e417-9 (published online on 15 July 2013).
9. Watanabe N, Nakahara Y, Taniguchi H, Kimura T, Kondoh Y, Kataoka K, Sakamoto K. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia. Acta Oncol. 2014;53:158-60.
10. Yanagisawa S, Inoue A, Koarai A, Ono M, Tamai T, Ichinose M. Successful crizotinib retreatment after crizotinib-induced interstitial lung disease. J Thorac Oncol. 2013;8:e73-4.